First Patient Enrolled in NUZYRA Trial for NTM Lung Disease

On October 18, 2021, biopharmaceutical company Paratek Pharmaceuticals, Inc. ("Paratek") shared via news release that the first patient had enrolled in a Phase 2b clinical trial. Within the trial, researchers…

Continue Reading First Patient Enrolled in NUZYRA Trial for NTM Lung Disease
XIPERE Approved in US for Uveitis Complication
source: pixabay.com

XIPERE Approved in US for Uveitis Complication

According to a news release from biopharmaceutical company Clearside Biomedical, Inc. ("Clearside") and eye health business Bausch + Lomb, a revolutionary treatment called XIPERE (triamcinolone acetonide injectable suspension) was recently…

Continue Reading XIPERE Approved in US for Uveitis Complication
Clinical Trial to Evaluate HMI-103 for PKU
source: pixabay.com

Clinical Trial to Evaluate HMI-103 for PKU

Previously, clinical-stage genetic medicines company Homology Medicines, Inc. ("Homology") submitted an Investigational New Drug (IND) application to the FDA for HMI-103, an investigational gene editing therapy designed to treat phenylketonuria…

Continue Reading Clinical Trial to Evaluate HMI-103 for PKU
ATYR1923 Safe and Effective for Pulmonary Sarcoidosis
Photo by Robina Weermeijer on Unsplash

ATYR1923 Safe and Effective for Pulmonary Sarcoidosis

Clinical trials can be helpful tools in determining the safety, efficacy, tolerability, recommended dose, and pharmacokinetics of specific drugs (among other things). In doing so, these trials help tell researchers…

Continue Reading ATYR1923 Safe and Effective for Pulmonary Sarcoidosis
The Secret Sauce for Bringing Innovative Therapies to Patients with Rare Diseases Faster
source: pixabay.com

The Secret Sauce for Bringing Innovative Therapies to Patients with Rare Diseases Faster

Written by Lori Lawter, MPH We’ve heard a lot about bringing drugs to market lately, especially in light of the COVID-19 vaccine.  You might wonder, “Is there a ‘secret sauce’…

Continue Reading The Secret Sauce for Bringing Innovative Therapies to Patients with Rare Diseases Faster

PTC-AADC Shows Benefits for Patients with AADC Deficiency, Data Shows

Recently, biopharmaceutical company PTC Therapeutics, Inc. performed a five-year data analysis to evaluate the continued safety, efficacy, and tolerability of PTC-AADC. The company developed this novel gene therapy to improve…

Continue Reading PTC-AADC Shows Benefits for Patients with AADC Deficiency, Data Shows